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2 
Introduction  
The conserved serine/threonine kinase mammalian target of rapamycin (mTOR) is a 
major regulator of survival growth, proliferation and motility in response to mitogens, 
energy as well as nutrient levels, exerting its effects through two distinct signaling 
complexes, known as mTOR complex (mTORC) 1 and mTORC2 (1, 2). In particular, the 
rapamycin-sensitive mTORC1 promotes cell growth and proliferation whereas mTORC2, 
rapamycin-non sensitive, is involved in the regulation of cell polarity and in the functional 
phosphorylation of cytoskeleton actin fibres (3-5). Therefore, mTOR functions as a 
central node in a complex network of signaling pathways that are involved both in normal 
physiological, as well as pathogenic events (6). mTOR signaling occurs in concert with 
upstream phosphoinositide-3-OH kinase (PI3K)/Akt and tuberous sclerosis complex 
(TSC) and several downstream effectors (7). Because of its central role in many different 
cellular activities, mTOR dysregulation can be involved in a great number of either 
inflammatory or neoplastic conditions through the coordinated phosphorylation of 
proteins that directly regulate cell-cycle progression and metabolism, as well as 
transcription factors that regulate the expression of genes involved in the oncogenic 
processes (6). The importance of mTOR signaling in oncology is now widely accepted, 
and agents that selectively target mTOR have been developed as anticancer drugs (8-11). 
Moreover, mTOR functions are also reported to be altered in metabolic disorders, such as 
obesity (5) and type 2 diabetes (12) as well as in autoimmune disorders, such as 
rheumatoid arthritis (13), inflammatory bowel disease (14) and lupus erythematosus (15).  
Recently, mTOR pathway was shown to play a role in regulating the immune response, 
not only in myeloid cells, but also in keratinocytes (16), potentially contributing to 
cytokines production in skin inflammation (17). Indeed, mTOR involvement in some of 
the most common inflammatory dermatoses has now been demonstrated (18).  
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  Chapter I  
mTOR 
 
mTOR structure 
mTOR was identified and cloned almost 20 years ago (1, 2, 19) after the discovery of the 
two yeast genes, TOR1 (target of rapamycin) and TOR2, in the budding yeast 
Saccharomyces cerevisiae during a screen for resistance to the immunosuppressant drug 
rapamycin (20, 21). Rapamycin, a macrocyclic lactone produced by Streptomyces 
hygroscopicus, was first isolated from a soil sample of Easter Island (Rapa Nui) during a 
program for anti-microbial agents in the early 1970s, and subsequently discovered to have 
equally potent immunosuppressive and anti-tumor properties (22-26). mTOR, also known 
as FRAP (FKBP12-rapamcyin-associated protein), RAFT1 (rapamycin and FKBP12 
target), RAPT 1 (rapamycin target 1), or SEP (sirolimus effector protein), is an ubiquitous 
and constitutively expressed serine/threonine kinase of 289 kDa (19, 27), member of the 
PI3K-kinase-related kinase (PIKK) superfamily since its C terminus shares strong 
homology to the catalytic domain of the lipidic kinase PI3K (19). However, there is no 
experimental evidence that it displays lipid kinase activity, and in this respect, it is similar 
to other protein kinases such as ATM and ATR (28).  
C-terminal end of mTOR includes the kinase catalytic domain (KIN). The KIN domain 
also presents a small region, called negative regulatory domain (NRD), that is probably a 
site of phosphoregulation (7, 29). Within this region, phosphorylation at thr2446, ser2448 
and ser2481 are correlated with overall higher levels of mTOR activity. Thr2246 is 
targeted by AMPK and S6K, ser2448 is a target of Akt and S6K, whereas ser2481 is an 
autocatalytic target of mTOR (30-33). Some of these residues are autophosphorylated 
even in the presence of rapamycin, whereas others are substrates of the downstream 
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effectors of mTOR itself, thereby providing multiple mechanisms for feedback regulation 
(7, 29).  
Immediately upstream of the catalytic domain is the FRB (FKBP12–rapamycin binding) 
domain, the site of inhibitory interaction between rapamycin and mTOR. Rapamycin 
bound to FK506 binding protein 12 (FKBP12) disrupts protein–protein interactions that 
are key to mTOR function (34). The FRB is also involved in the interaction between 
mTOR and other mTOR complex members including Raptor and Ras homolog enriched 
in the brain (Rheb). In addition, mTOR contains a relatively large FAT domain, which is 
also present in other PIKK proteins (35). A second FAT domain (FATC) is located at the 
distal C-terminal end of mTOR. Both FAT domains are absolutely necessary for mTOR 
catalytic function and the deletion of even a single amino acid from this domain abrogates 
the activity (36, 37).  
The N-terminal portion of mTOR contains 20 tandem HEAT (Huntignton, EF3, A 
subunit of PP2A, TOR1) repeats. Each HEAT repeat consists of two α-helices of 40 
amino acids, each with a specific pattern of hydrophobic and hydrophilic residues. 
Tandem HEAT repeats are present in many proteins and are implicated in protein–protein 
interactions (38). 
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mTOR complexes 
Cumulative evidence indicates that mTOR acts as a “master switch” of cellular anabolic 
and catabolic processes, regulating the rate of cell growth and proliferation by its ability 
to sense mitogen, energy and nutrient levels (39, 40). mTOR functions as two distinct 
signalling complexes known as mTOR complex (mTORC) 1 and mTORC2 (30). These 
complexes share some common constituents such as the G-like protein family member 
(mLST8) and DEP-domain-containing mTOR-interacting protein (Deptor) but can be 
largely distinguished by their unique components (3, 4, 29).  
The rapamycin and nutrient-sensitive complex, mTORC1, consisting of mTOR, mLST8 
and Raptor (regulatory associated protein of mTOR) was first reported in 2002 (3, 41). 
The main function of mTORC1 is to regulate cell growth, proliferation and survival by 
sensing mitogen, energy and nutrient signals (42). Raptor acts as a scaffolding companion 
to mTOR, binding TOR signaling (TOS) motif-containing proteins and shuttling them to 
the mTOR catalytic domain (3, 7). mTORC1 is sensitive to rapamycin via competition 
between Raptor and FKBP12–rapamycin for binding to the FRB domain (3). In addition 
to Raptor, mTORC1 contains other proteins such as proline-rich Akt/PKB substrate 40 
kD (PRAS40). PRAS40 regulates mTOR–Raptor interactions and negatively regulates 
mTOR signaling by blocking mTORC1 access to its substrates (43). However, in another 
study, PRAS40 was required for substrate activation, suggesting that in some contexts 
facilitates mTORC1 function. The interaction between mTOR and PRAS40 is disrupted 
by rapamycin, indicating that FKBP12 can mediate its nascent inhibitory activity (43-45). 
mTORC2, the second distinct mTOR complex, was identified in 2004 (4, 29). It was 
originally thought to be rapamycin-insensitive (4). However, further studies demonstrated 
that prolonged rapamycin treatment inhibits the assembly and function of mTORC2 in 
some cell lines as well (46). mTORC2 regulates the actin cytoskeleton by mediating 
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phosphorylation state of protein kinase C α (PKCα) (4), and modulates cell survival in 
response to growth factors by phosphorylating its downstream effector Akt (protein 
kinase B, PKB) at the hydrophobic motif site, S473 (29, 47, 48). Like mTORC1, 
mTORC2 also includes mTOR and mLST8, but instead of Raptor, mTORC2 contains 
two special subunits, Rictor and mammalian stress-activated protein kinase (SAPK)-
interacting protein 1 (mSin1) (4, 29, 49).  Sin1 encodes an essential function because the 
deletion of Sin1 is embryonically lethal (50). Another recently identiﬁed mTORC2 
component is protein observed with Rictor (Protor). Protor binds Rictor independently of 
mTOR and does not appear to be required for mTORC2-mediated Akt activation (50-53). 
In addition, PRR5 (proline-rich protein 5) and Hsp70 are other novel components of 
mTORC2 (54-57). 
Both mTOR complexes function predominantly in the cytoplasm. However, experiments 
using a nuclear export receptor inhibitor indicate that mTOR may actually be a 
cytoplasmic-nuclear shuttling protein. This nuclear shuttling appears to play a role in the 
phosphorylation of mTORC1 substrates induced by mitogenic stimulation and in the 
consequent upregulation of translation (58). This dual subcellular localization was also 
demonstrated by immunohistochemical analysis (IHC) in a study on human carcinomas. 
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Upstream regulators of mTOR  
As described above, mTOR integrates various signals to regulate cell growth and 
proliferation. A number of biologically important stimuli have been shown to induce 
mTOR signaling: growth factors, nutrients (amino-acid, glucose and oxygen etc.), energy 
and stress (59).  
For example, binding of insulin or insulin-like growth factor (IGF) to its receptor (IGFR) 
leads to the recruitment and phosphorylation of insulin receptor substrate (IRS). IGFR 
and IRS then interact with PI3K through specific phosphorylated tyrosine residues which 
lead to the activation of mTOR (7).  PI3K phosphorylates phosphatidylinositol-4-5-bis-
phosphate (PIP2) to form phosphatidy-linositol-3-4-5-trisphosphate (PIP3), which binds 
to Akt as well as PDK1 and facilitates their relocalization to the membrane. 
Colocalization of Akt with PDK1 results in the partial activation of Akt through 
phosphorylation at thr308 (60). Full activation of Akt requires additional phosphorylation 
at ser473 by the putative kinase PDK2, which includes mTORC2 complex, mitogen-
activated protein kinase (MAPK)-activated protein kinase and other kinases (7, 36, 61, 
62). Thus, mTORC2 performs a positive feedback role in the activation of Akt, and could 
thereby indirectly activate mTORC1. Akt suppresses the activity of the downstream 
TSC1/2 complex which otherwise inhibits the activity of Rheb (7). This TSC1/2 complex 
functions as a key player in the regulation of the mTOR pathway by mediating inputs 
from the PI3K/PTEN/Akt and Ras/Erk1/2 signaling pathways, and by regulating 
translation initiation in response (63). Activated Erk1/2 directly phosphorylates TSC2 at 
ser664, (and possibly ser1798 as well) (49, 64). This site differs from those 
phosphorylated by Akt (ser939, the1462 and possibly additional sites) (65), but either 
causes functional inactivation of TSC1/2. Of note, TSC2 is also a substrate of S6K (59). 
Conversely, PIP3 accumulation is antagonized by the lipid phosphatase PTEN 
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(phosphatase and tensin homolog deleted on chromosome 10), which converts PIP3 to 
PIP2 (63, 66). Therefore, one critical outcome of PTEN inactivation is an increase in 
mTOR activity (63). Rheb, in turn, binds directly to the kinase domain in mTOR and 
drives the formation of that mTOR-Raptor complex in a GTP-dependent manner (67, 68).  
Other mTOR activators are amino acids, in particular, leucine, which enhances mTORC1 
activation via inhibition of  TSC1/2 or via stimulation of Ras homologue enriched in 
brain (Rheb), which is a small GTPase required for mTOR activation (7, 69).  
Moreover, mTORC1 indirectly senses the energy status of the cell through the liver 
kinase (LK) B1-mediated pathway, which functions in parallel to the PI3K pathway. 
LKB1, a tumor suppressor inactivated in Peutz-Jeghers syndrome, activates AMP-
activated kinase (AMPK) in response to energy deprivation (66). This activation of 
AMPK in response to low cellular energy (high AMP/ATP ratio) downregulates 
energetically demanding processes, such as protein synthesis, and stimulates ATP-
generating processes. Activated AMPK also phosphorylates and activates TSC2 by 
enhancing its GAP activity, resulting in the inhibition of mTORC1 (66).  
Lastly, mTOR activity is repressed not only under conditions of energy deprivation, but 
also conditions of stress, such as hypoxia, heat shock, and low cellular energy state (70). 
The hypoxic signal is transduced to mTORC1 via two homologous proteins REDD1 and 
REDD2, which are upregulated by HIF-1α. REDD acts downstream of PI3K and 
functions to inhibit mTORC1 signaling (70).    
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Downstream targets of mTOR 
The major targets of mTOR are components of the translation machinery, and in 
particular, those responsible for ribosome recruitment to mRNA (71). Indeed, translation 
is regulated in most instances at the step during which a ribosome is recruited to the 5’end 
of an mRNA, positioned at a start codon (72). The 5’end of all nuclear-transcribed 
mRNAs possess a cap structure (m7GpppN, in which “m” represents a methyl group and 
“N”, any nucleotide) that is specifically recognized by eukaryotic translation initiation 
factor 4E (eIF4E). eIF4E is part of the pre-initiation complex eIF4F containing the large 
scaffolding proteins eIF4GI and eIF4GII and the RNA helicase eIF4A (72-74). Following 
its binding to the 5’cap, eIF4F unwinds the mRNA 5’-proximal secondary structure and, 
in association with several other initiation factors, allows the binding of the 40S ribosomal 
subunit (72). Strikingly, several components of the ribosome recruitment machinery as 
well as ribosomal components are either direct or indirect targets of mTOR (71). In 
mammals, S6Ks and 4E-BPs are the best characterized downstream targets of mTOR. 4E-
BPs, a family of translational repressor proteins, consists of three low molecular weight 
proteins, 4EBP1, 4E-BP2, and 4E-BP3 (75-77). 4E-BP1 is directly phosphorylated by 
mTORC1. Hypophosphorylated 4E-BP1 binds tightly to eIF4E, the mRNA cap-binding 
protein, and represses cap-dependent translation by blocking the binding of eIF4E to 
eIF4G. In response to sufficient growth factors and nutrients stimulation, seven sites (Thr 
37, Thr 46, Ser 65, Thr 70, Ser 83, Ser 101 and Ser 112) of 4E-BP1 can be phosphorylated 
(78). The phosphorylation of 4E-BP1 at multiple site results in its dissociation from 
eIF4E, allowing eIF4E to engage eIF4G (76, 79). eIF4G serves as a scaffold protein for 
the assembly of other initiation factors including eIF4A, which acts as an ATP-dependent 
RNA helicase, and further interacts with eIF3, which recruits the 40S ribosome to the 
5’end of the mRNA (80). 
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Mammalian cells contain two similar S6 kinase proteins, S6K1 and S6K2 (81). S6K2, 
which has 70% overall amino acid identity with S6K1, was discovered much later than 
S6K1 (82). Both the activation of S6K1 and S6K2 are regulated by mTOR (83, 84). S6K1 
is known as the major ribosomal protein S6 (rpS6) kinase in mammalian cells and is 
pointed as a key player in the control of cell growth (cell size) and proliferation (85-87). 
Early studies suggested that activated S6K1 regulates protein synthesis through 
phosphorylation of the 40S ribosomal protein S6, and this was thought to increase the 
translational efficiency of a class of mRNA transcripts with a 5’-terminal 
oligopolypirymidine (5’-TOP) (88, 89). These mRNAs encode exclusively for 
components of the translation machinery, including all ribosomal proteins, elongation 
factors, and poly(A)-binding protein (PABP). Critical data supporting the idea that S6K1 
is required for 5’-TOP mRNA translation include the demonstration that a rapamycin-
resistant S6K1 mutant confers rapamycin resistance to the translation of 5’-TOP mRNAs 
(89). As an alternative to S6, eIF4B is a physiologically relevant target of S6K1 that could 
explain its effect on translation and cell growth. As stated above, eIF4B is required for 
efficient recruitment of ribosomes to mRNA (73). eIF4B is an RNA-binding protein that 
specifically stimulates the ATPase and RNA helicase activities of eIF4A (90). eIF4B is 
phosphorylated in response to a variety of extracellular stimuli, such as serum, insulin, 
and phorbol esters that promote cell growth and proliferation (91). 
In addition, mTOR is also involved in the regulation of some proteins including CLIP-170 
(cytoplasmic linker protein-170) (92), eukaryotic elongation factor 2 (eEF2) kinase (93), 
ornithine decarboxylase (ODC) (94), glycogen synthase (95), hypoxia-inducible factor 1α 
(HIF-1α) (96, 97), lipin (98) PKCδ and PKCε (99) protein phosphatase 2A (PP2A) (100), 
p21Cip1 and p27Kip1 cyclin-dependent kinase inhibitors (101, 102), retinoblastoma 
protein (Rb) (103), and signal transducer and activator of transcription 3 (STAT3) (104).  
 
 
 
11 
 
 
 
 
 
 
 
 
 
 
 
12 
   Chapter II  
mTOR and diseases 
 
mTOR and disease 
Because of its central role in cellular functions, mTOR dysregulation is involved in a 
number of either inflammatory or neoplastic conditions. In support of this, the importance 
of mTOR in the immune system has long been recognized through the finding of the 
immunosuppressive role of rapamycin. Indeed, rapamycin is used to prevent post-
transplantation allograft rejection in kidney transplant recipients, because, inhibiting 
mTOR, it strongly suppresses interleukin-2 (IL-2) stimulated T cell proliferation (105). 
Moreover, regulatory T cells (Tregs) induction is inhibited by mTOR activation and is 
enhanced by rapamycin (106), in fact, in mTOR knockout mice Treg phenotype is 
enhanced whereas T helper cells 1 (Th1), Th2 and Th17 lineages differentiation is 
abrogated (107). Furthermore, in many recent studies, other than T-cells, also dendritic 
cells (DCs) functions have been shown influenced by mTOR signalling pathways. In vivo 
or in vitro rapamycin administration can impair maturation and differentiation of DCs 
which remain tolerogenic and fail to upregulate co-stimulatory molecules (108, 109).  
mTOR is frequently dysregulated in cancer and its inhibitors, temsirolimus and 
everolimus, are used in patients with renal cell carcinoma who had poor prognosis or had 
failed prior therapies (8, 9). Temsirolimus was reported to be efficacious in treatment of 
refractory mantle cell lymphoma (10), whereas everolimus was recently reported to 
increase progression-free survival in patients with advanced pancreatic neuroendocrine 
tumours (11). However, despite isolated successes in subsets of cancer, the performance 
of mTOR inhibitors has been undistinguished, suggesting that the full therapeutic 
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potential of targeting mTOR has yet to be exploited. Moreover, mTOR functions are 
reported to be altered in metabolic disorders, such as obesity (105) and type 2 diabetes 
(12) as well as in inflammatory and autoimmune disorders such as rheumatoid arthritis 
(13), inflammatory bowel disease (14) and lupus erythematosus (15). The mTOR 
pathway has been shown to play a role in regulating the immune response, not only in 
myeloid cells but also in keratinocytes (16) and potentially contributes to cytokine 
production in psoriasis (17). As psoriasis is also considered a hyper-proliferative disorder, 
thus requiring enhanced cell growth, mTOR signalling could be activated in psoriatic 
lesions suggesting a possible role in the pathogenesis of the disease. Recent studies have 
also hypothesized a possible role for mTORC1 in acne pathogenesis (110). Acne is an 
inflammatory process involving the pilosebaceous unit, with a prevalence rates of over 
85% in adolescents (111). Western diet (WD), characterized by high glycemic load and 
high dairy protein consumption, has been suggested to be a fundamental acne promoting 
factor (112, 113). High milk and dairy intake, as well as hyperglycemia, determine an 
over-stimulation of insulin and insulin-like growth factor (IGF)-1 mediated signals (114); 
this results in Akt phosphorilation with inhibition of TSC1 and 2, negative upstream 
regulators of mTOR, and consequent mTORC1 and mTORC2 activation (115).  
mTORC1 activates sterol regulatory element-binding protein (SREBP), the master 
transcription factor of lipogenesis, and increases androgen hormone secretion (116). 
mTORC1, directly activated by testosterone, amplifies androgen signaling of sebaceous 
follicles (110). Indeed, testosterone is able to increase the phosphorylation of mTOR and 
its major downstream effectors eukaryotic translation initiation factor 4E-binding protein 
1 (4EBP1) as well as ribosomal protein S6 kinase beta-1 (S6K1) (117).  
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Pathogenesis of psoriasis 
Psoriasis is a complex multifactorial disease, where various environmental triggers (e.g. 
trauma, stress, infections and drugs) promote, in genetically predisposed individuals, the 
activation of an exaggerated and poorly controlled immuno-inflammatory response in the 
skin characterized by hyperplasia of epidermal keratinocytes, vascular hyperplasia and 
ectasia, infiltration of T lymphocytes, neutrophils and other types of leucocytes. 
Therefore, rather than viewing psoriasis as a disease caused by a single cell type or a 
single inflammatory cytokine, it is probably best to conceptualize its pathogenesis as 
linked to many interactive responses between infiltrating leucocytes, resident skin cells, 
and an array of proinflammatory cytokines, chemokines, and chemical mediators 
produced in the skin under regulation of the cellular immune system. Dendritic cells 
(DCs), the most potent APCs (antigen-presenting cells), are sentinels of the immune 
system. In normal skin, DCs are found in the epidermis [LCs (Langerhans cells)] and 
dermis (myeloid and plasmacytoid DCs). LCs reside in the suprabasal layers of the 
epidermis in close contact with keratinocytes. After activation, LCs up-regulate 
chemokine receptors on their surface and migrate to skin-draining lymph nodes, where 
they present antigenic peptides they have encountered in the skin to naïve T-cells. The 
mobilization of LCs into draining lymph nodes in response to stimuli that normally 
induce migration [e.g. chemical allergen, TNF-α and IL -1β] is largely absent in psoriasis 
(118) These findings raise the possibility that LCs retained within the epidermis present 
antigens locally and exacerbate the ongoing inflammatory reaction. In the inflamed 
dermis of psoriatic patients, there is a marked increase in myeloid CD11c+ DCs. These 
cells, probably derived from circulating DC precursors, migrate into the skin in response 
to chemotactic signals and synthesize high levels of pro-inflammatory cytokines (e.g. IL-
12 and IL-23) (119). The dermal CD11c+ DCs which make TNF-α and iNOS (inducible 
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nitric oxide synthase) (TIP-DCs) are thought to be the human equivalent of a similar DC 
subset which is needed for the clearance of some pathogens in mice. There are also 
increased numbers of plasmacytoid DCs in psoriatic skin compared with normal skin. 
These express TLR (Toll-like receptor) 9 and produce large amounts of IFN (inteferon)-α 
when activated with the microbicidal cathelicidin LL37 bound to self-DNA fragments 
released by stressed or dying cells in the skin (Figure 1) (120). Plasmacytoid DC also 
express TLR8 and make IFN-α when stimulated with self-RNA–LL37 complexes. LL37 
can also bind self-RNA released by dying cells, and these complexes activate TLR7 in 
plasmacytoid DCs and, like self-DNA–LL37 complexes, trigger the secretion of IFN-α. 
In contrast with self-DNA–LL37 complexes, self-RNA–LL37 complexes can interact 
with TLR8 on classical myeloid DCs and promote their differentiation into mature DCs 
with secretion of TNF-α and IL-6. Consistently, in mice, topical applications of the 
TLR7/TLR8 ligand imiquimod induce psoriasis-like skin inflammation. KCs can be 
viewed as an integral part of the skin-resident immune system, because they may act as 
APCs, produce innate immune mediators, and contribute to the skin homing and local 
activation of immune cells. KCs express TLRs and respond to microbial stimuli by 
producing large amounts of cytokines (e.g. TNF-α, IL-1α, IL-6 and IL-18), chemotactic 
chemokines [e.g. IL-8 and CCL20 (CC chemokine ligand 20)] and antimicrobial peptides 
[e.g. HBD (human β-defensin)-2, HBD-3 and LL37].  Moreover, the psoriatic plaque is 
characterized by a marked infiltration of activated CD4+ and CD8+ T-cells. CD4+ T-
cells infiltrate mainly the dermis, whereas CD8+ T-cells are present in the epidermis. Th 
(helper) 1 and Th2 are the best understood effector CD4+ T-cells formed during immune 
responses. Th1 cells produce IFN-γ and TNF-α, and mediate immune responses against 
intracellular bacteria, viruses and tumour cells. Th2 cells make mostly IL-4, IL-5 and IL-
13, and stimulate humoral responses against extracellular parasites. Another subset of Th 
cells, termed Th17 cells, which are predominantly CD161-expressing cells, secrete IL-
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17A and IL-17F, and are involved in the activation of neutrophils and immunity to 
bacteria and fungi. TGF-β1 (transforming growth factor-β1) concentration and the 
concomitant presence of at least one proinflammatory cytokine are key factors in human 
Th17 differentiation. These cells, together with Th1 cells, (121),  appear to lie at the very 
heart of the pathogenesis of psoriasis (119). Indeed, IL-17 produced by Th17 cells was 
shown to promote the production of IL-6, IL-8, GM-CSF (granulocyte/macrophage 
colony-stimulating factor) and ICAM-1 (intercellular adhesion molecule-1) in KCs, 
synergizing with IFN-γ. They can also produce IL-21, IL-22 and IL-26. IL-21 acts on 
Th17 cells to amplify its own synthesis. IL-21 also up-regulates IL-23R expression on T-
cells, thus making Th17 cells responsive to IL-23. Altogether, these events generate a 
positive-feedback loop that helps amplify the Th17 lineage. More recently, it has been 
shown that the IL-22 expression profile may differ from that of IL-17A, and that IL-22-
producing T-cells, termed Th22 cells, could represent a T-cell subset that is distinct from 
typical Th17 cells (122) Traditionally, psoriasis has been classified as a Th1-associated 
disease, because T-cells infiltrating the lesional skin of psoriatic patients produce high 
levels of IFN-γ. IL-12, the major Th1-inducing factor in humans, is also highly expressed 
(Figure1). However, in the psoriatic plaque, there is also elevated synthesis of Th17-
related cytokines, such as IL-17A, IL-17F, IL-21 and IL-22 (Figure 1), as well as 
enhanced production of IL-23, a heterodimeric cytokine composed of IL-23p19 and IL-
12p40 subunits which amplifies Th17 cell responses and causes psoriasis lesions when 
administered intradermally to mice.  A functional role of Th17 cells in psoriasis is 
suggested by the demonstration that both IL-21 and IL-22 can induce keratinocyte 
hyperplasia and that Th17 cytokine levels decrease during successful anti-TNF-α 
treatment. IL-22 also triggers the production of antimicrobial peptides and expression of 
genes involved in epidermal differentiation and survival. Studies in mice have shown that 
IL-22 induces keratinocyte hyperplasia and acanthosis, and that some biological effects of 
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IL-22 are amplified by TNF-α, as a result of the ability of TNF-α to enhance IL-22 
receptor expression (122). Both Th1 and Th17 cytokines induce keratinocytes to produce 
CCL20, a chemoattractant for CCR6-expressing DCs and T-cells, thus providing a 
positive feedback loop that sustains the accumulation of these cells in the psoriatic skin. 
IL-17A and IL-22 are powerful inducers of IL-20 by DCs and proliferating keratinocytes. 
IL-20 is highly produced in psoriasis, and its overexpression in transgenic mice causes 
epidermal thickening. Interestingly, the skin alterations in IL-20-transgenic mice occur 
without immune cell infiltration, suggesting that IL-20 is a downstream mediator in the 
psoriasis-associated immuno-inflammatory cascade. Therefore the IL-23/Th17 pathway 
appears to be central in the pathogenesis of psoriasis, orchestrating both the induction and 
maintenance of skin inflammatory response by regulating the secretion of inflammatory 
cytokines and chemoattractants, and the proliferative response of psoriatic KCs through 
the production of mitogenic cytokines (IL-22 and IL-21). 
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Pathogenesis of acne 
Acne is an inflammatory process involving the pilosebaceous unit-hair follicles in the skin 
with a prevalence rates of over 85% in adolescents (111). The clinical features of acne 
include seborrhoea (excess grease), non-inflammatory lesions (open and closed 
comedones), inflammatory lesions (papules and pustules), and various degrees of scarring. 
The distribution of acne corresponds to the highest density of pilosebaceous units (face, 
neck, upper chest, shoulders, and back). Nodules and cysts comprise severe nodulocystic 
acne.  
Four processes have a pivotal role in the formation of acne lesions: inflammatory 
mediators released into the skin; alteration of the keratinisation process leading to  
comedones; increased and altered sebum production under androgen control (or increased 
androgen receptor sensitivity) and follicular colonisation by P acnes. (123). The exact 
sequence of events and how they and other factors interact remains unclear.  
Inflammatory acne process might involve CD4+ lymphocytes and macrophages (124). 
Defective terminal keratinocyte differentiation leads to comedo formation under the 
influence of androgens and qualitative changes in the sebum lipids that induce IL-1 
secretion (125). Sebaceous glands are an important part of the innate immune system, 
producing a variety of antimicrobial peptides, neuropeptides, and antibacterial lipids such 
as sapienic acid. Each sebaceous gland functions like an independent endocrine organ 
influenced by corticotrophin-releasing hormone, which might mediate the link between 
stress and acne exacerbations (126). Vitamin D also regulates sebum production, and IGF-
1 might increase sebum through sterol-response element-binding proteins (SREBs) (127). 
Matrix metalloproteinases in sebum have an important role in inflammation, cell 
proliferation, degradation of the dermal matrix, and treatment responsiveness (128). 
Sebaceous follicles containing a microcomedone provide an anaerobic and lipid-rich 
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environment in which P acnes flourishes (129). Lipogenesis is directly augmented by P 
acnes (130). Colonization of facial follicles with P acnes follows the asynchronous 
initiation of sebum production which might explain why treatment with isotretinoin too 
early can need to be followed up with subsequent courses, as new previously P acnes-
naive follicles become colonized and inflamed. Unique P acnes strains with different 
bacterial resistance profiles colonize different pilosebaceous units and induce 
inflammation by the activation of toll-like receptors in keratinocytes and macrophages 
(131) In-vitro work suggests that P acnes could behave like a biofilm within follicles, 
leading to decreased response to antimicrobial agents (132). P acnes resistance to 
commonly used oral antibiotics for acne affects treatment response, suggesting that direct 
antimicrobial effects might be important in addition to the anti-inflammatory actions of 
antibiotics.(133). 
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Chapter III 
Experimental Design 
Objective: 
Based on the association of mTOR with inflammatory conditions, we sought to 
investigate its possible involvement in cutaneous inflammation. Indeed, although the 
current interest in the development of mTOR inhibitors is focused almost exclusively on 
their potential as anticancer agents, a better understanding of mTOR biology/complex 
signalling might lead to new therapeutic employments, also in inflammatory diseases. 
 
Materials and methods 
Human subjects 
The overall study population included: 15 patients affected by moderate-to-severe 
psoriasis, 5 patients with allergic contact dermatitis (ACD), 5 patients with atopic 
dermatitis (AD), 3 patients affected by colon cancer with hepatic and lymph nodes 
metastases presenting a skin inflammatory rash induced by cetuximab, an epidermal 
growth factor receptor (EGFR) inhibitor, 5 patients with acne and 10 healthy controls. All 
the patients were i) in a similar age range ii) not affected by other comorbidities and iii) in 
1-month wash out period from systemic treatment. 3 mm skin biopsies were performed to 
all patients in the skin affected by the dermatosis and in uninvolved, clinically normal 
skin. In addition, skin specimens (3 mm Ф) were taken from psoriatic plaques of 5 
patients before (T0) and after 16 weeks (T1) of treatment with adalimumab, an inhibitor 
of tumor necrosis factor-α (TNF-α) (administered subcutaneously 80 mg at week 0 and 
successively 40mg eow). Healthy skin specimens, obtained from 10 healthy donors, who 
had undergone plastic surgery, were used as controls. Blood samples were obtained from 
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5 healthy volunteers as well as 5 patients with psoriasis for the isolation of peripheral 
blood mononuclear cells (PBMC). The experimental protocol was approved by the Ethics 
Committee of our institution and was conformed to the principles outlined in the 
Declaration of Helsinki. Each subject gave written informed consent before entering the 
study.  
 
Purification of PBMC 
PBMC were separated by density gradient centrifugation over Ficoll-Paque Plus (GE 
Healthcare, Uppsala, Sweden). Total RNA was isolated by RNeasy Mini Protocol 
(Qiagen, Valencia, CA, U.S.A.) and cDNA was prepared (Transcriptor High Fidelity 
cDNA Synthesis; Roche, Indianapolis, IN, U.S.A.) according to the manufacturer’s 
instructions.  
 
Ex vivo full-thickness skin organ culture 
Skin biopsies (3 mm diameter and length) of 10 healthy subjects undergoing to plastic 
surgery were cultured as follows: a hole was punched in a transwell filter (pore size 1 µm; 
Beckton Dickinson Labware, Franklin Lakes, NJ); the biopsy was placed in a 12-well 
culture plate (Beckton Dickinson Labware) containing 1 ml medium with the epidermis 
facing upwards at the liquid-air interface and the dermis suspended in the culture 
medium. Biopsies were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
GIBCO, Grand Island, NY) containing 10% FBS (GIBCO), 2 mM L-glutamine (GIBCO) 
and antibiotics (100 IU/ml penicillin G, 100 µg/ml streptomycin, GIBCO) under normal 
conditions (atmosphere containing 5% CO2 at 37°C). Incubation with TNF-α (GIBCO) 
and IL-17A (Biosource International, Camarillo, CA) was performed at 20 ng/ml and 10 
ng/ml, respectively, for 24 h.  
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Cell cultures  
HaCaT cells were grown in DMEM, GIBCO, containing 10% fetal bovine serum (FBS, 
GIBCO), 2 mM L-glutamine (GIBCO) and antibiotics (100 IU/ml penicillin G, 100 µg/ml 
streptomycin, GIBCO). Human epidermal keratinocytes (KCs) were isolated from normal 
healthy skin of surgical remnants. Single-cell suspensions of KCs were prepared using 
standard methods (19).  KCs used for experiments were in the second or third passage. 
Both cells were cultured at 37°C with 5% CO2 in air. For in vitro stimulation assays, 
HaCaT cells and primary KCs, at 70–80% confluence, were stimulated with TNF-α (20 
ng/ml GIBCO), IL-17A (10 ng/ml Biosource International, Camarillo, CA), or their 
combination for 24h. HaCaT cells were also irradiated with 100mJ/cm² of ultraviolet 
(UV)B (TL12 lamp Philips, Eindhoven, The Netherlands) and cultured for 24h. 
 
RNA extraction, cDNA synthesis and quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) 
RNA was extracted (RNeasy Mini Protocol Qiagen, Valencia, CA) from skin biopsies as 
well as cell cultures and cDNA was prepared (Transcriptor High Fidelity cDNA 
Synthesis, Roche, Indianapolis, IN) according to the manufacturer’s instructions. qRT-
PCR (LightCycler, Roche) was used to analyze levels of expression of mTOR and its 
major up-stream as well as down-stream regulators such as tuberous sclerosis protein 
(TSC) 1 and 2, Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and 
Ribosomal protein S6 kinase beta-1 (S6K1). Relative mRNA levels were determined by 
the comparative threshold cycle method, and their expression was normalized to the 
expression of 18S mRNA. PCR primers (mTOR, TSC1, TSC2, 4EBP1, S6K1, 18S) were 
designed based on published sequences, and their speciﬁcity was veriﬁed with BLAST 
alignment search. To conﬁrm ampliﬁcation of the expected size fragment, ampliﬁcation 
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products were characterized by agarose gel electrophoresis. Melting curve analysis was 
carried out after completion to confirm the presence of single amplified species.  
 
Immunohistochemistry 
The immunohistochemical detection of mTOR was carried out on lesional and non 
lesional skin samples of 5 psoriatic and 5 acneic patients. Healthy skin samples were used 
as controls. Skin samples were immediately placed in tissue freezing medium 
(Jung, Leica, Wetzlar, Germany) and stored at −80° C. Five micrometer sections were cut 
with a cryostat and fixed with cold methanol for 10 min. The Vectastain Elite ABC Kit 
(Vector Laboratories, Burlingame, CA) was used as follows: sections were incubated 
with blocking solution (horse serum diluted in buffer: phosphate buffered saline  [PBS] + 
bovine serum albumin 1%) for 20 min at 22° C. Biopsies were stained with rabbit anti-
human mTOR (2.5 µg/ml LS-B650 IHC-plus LifeSpan BioScieces) and incubated 
overnight at 4° C. The sections were then washed in buffer and incubated with 
biotinylated secondary antibody for 30 min at room temperature. Peroxydase activity was 
revealed using DAB substrate (ImmPACT DAB, Burlingame, CA). Counterstaining was 
performed with hematoxylin. 
  
Statistical analyses 
All statistical analyses were performed using GraphPad Prism 4.0 (GraphPad Software 
Inc, La Jolla, CA). Student’s t test or ANOVA (when comparing more than 2 groups) 
were used to calculate statistical differences. Values of p < 0.05 were considered 
significant.  
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Results 
mTOR gene expression is increased in skin inflammatory diseases 
mTOR gene expression was significantly increased in psoriasis, ACD, AD as well as in 
EGFR inhibitor induced cutaneous rash, compared to healthy skin (Fig. 1A). Psoriasis 
mTOR expression was also enhanced in non-lesional skin of psoriatic patients respect to 
healthy skin (Fig. 1B). Conversely, mTOR gene expression resulted decreased in PBMC 
isolated from psoriatic subjects when compared to healthy controls (Fig. 1C). 
 
 
Fig. 1. mTOR gene expression in inflammatory skin diseases: A) psoriasis, ACD, AD and EGFR-inhibitor-
induced cutaneous rash; B) psoriatic lesional and non lesional skin. Data were compared with healthy skin, 
normalized to the housekeeping gene 18S and expressed as mean ± SD. C) healthy and psoriatic PBMC. 
Data were compared with healthy PBMC, normalized to the housekeeping gene 18S and expressed as mean 
± SD. ACD=allergic contact dermatitis, AD=atopic dermatitis, EGFR=epithelial growth factor receptor, 
les=lesional, PBMC=peripheral blood mononuclear cells, SD=standard deviation, *p<0.05, **p<0.01, 
***p<0.001 
 
 
mTOR up-stream regulators and down-stream effectors in skin 
inflammatory diseases 
To evaluate the effective enhancement of mTOR in these skin inflammatory diseases we 
also investigated the expression of mRNA levels of key negative upstream regulators of 
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mTOR such as TSC1 and TSC2. TSC1 and TSC2 gene expression were not enhanced in 
psoriasis and ACD and were significantly reduced in AD compared to healthy skin (Fig. 
2A-B); particularly, as regards EGFR inhibitor induced cutaneous rash, TSC1 levels were 
not significantly increased, whereas TSC2 gene expression was reduced.  
 
 
Fig. 2. A) TSC1 and B) TSC2 gene expression in psoriasis, ACD, AD and EGFR-inhibitor-induced 
cutaneous rash. Data were compared with healthy skin, normalized to the housekeeping gene 18S and 
expressed as mean ± SD. ACD=allergic contact dermatitis, AD=atopic dermatitis, EGFR=epithelial growth 
factor receptor, SD=standard deviation, TSC1=tuberous sclerosis protein 1, TSC2=tuberous sclerosis 
protein 2, *p<0.05, **p<0.01, ***p<0.001 
 
Since our experiments showed that mTOR may be involved in skin inflammation we have 
also investigated gene expression of its major downstream effectors such as 4EBP1 and 
S6K1, which are known as the best output of mTORC1. Neither 4EBP1 nor S6K1 were 
significantly augmented in psoriasis, AD, ACD or EGFR inhibitor induced cutaneous 
rash (Fig. 3A-B). 
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Fig. 3. A) 4EBP1 and B) S6K gene expression in psoriasis, ACD, AD and EGFR-inhibitor-induced 
cutaneous rash. Data were compared with healthy skin, normalized to the housekeeping gene 18S and 
expressed as mean ± SD. ACD=allergic contact dermatitis, AD=atopic dermatitis, 4EBP1= Eukaryotic 
translation initiation factor 4E-binding protein 1, EGFR=epithelial growth factor receptor, SD=standard 
deviation, S6K= Ribosomal protein S6 kinase beta-1 (S6K), *p<0.05, **p<0.01, ***p<0.001 
 
 
mTOR is strongly expressed in psoriasis (both lesional and non-lesional 
skin) 
As an additional confirmation, immunohistochemical studies demonstrated that mTOR 
was effectively over-expressed in skin inflammatory diseases. In particular, as regards 
psoriasis, mTOR kinase was equally strong expressed through all epidermal layers in 
lesional (Fig. 4A) as well as non-lesional psoriatic skin (Fig. 4B); but only weakly 
expressed in the epidermis from healthy individuals (Fig. 4C). 
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Fig. 4. Immunohistochemical detection of mTOR in A-B-C) lesional psoriatic skin; D-E) non lesional 
psoriatic skin and F-G) healthy skin; F) negative control. DAB staining X6 (A, D, F, H), X25 (B, E, G), 
X40 (C). Each picture is representative of data from 5 different patients affected by moderate-to-severe 
psoriasis or healthy subjects. PSO LES=psoriatic lesional skin; PSO NON LES=psoriatic non lesional skin; 
HS=healthy skin 
 
 
 
28 
 
 
mTOR gene expression is increased by UVB irradiation, but not by 
TNF-α and IL-17A 
Given that mTOR was enhanced in skin inflammatory diseases, we sought to analyze if a 
pro-inflammatory setting was determinant for mTOR induction in KCs as well as skin 
organ culture. More specifically, we investigated whether UVB irradiation or psoriasis-
associated Th1 and Th17 cytokines could interfere with mTOR gene expression. Our 
results showed that IL-17A, TNF-α or their combination, were not able to increase 
mTOR, neither in HaCaT nor in KCs cultures and in ex vivo full-thickness skin organ 
culture (Fig. 5A-C). Interestingly, 100mJ/cm² UVB irradiation was able to slightly 
increase mTOR gene expression in HaCaT cells (Fig. 5A). 
 
mTOR gene expression in psoriasis is not altered by anti-TNF-α 
treatment 
Since mTOR was enhanced in psoriasis plaques, we sought to investigate if a proper 
systemic treatment was able to down-regulate it. More specifically, we assessed mTOR 
gene expression in lesional psoriatic skin of 5 patients before and after 16 weeks of anti-
TNF-α treatment. Although clinical improvement was assessed in all patients, with 60% 
(n=3) of them reaching PASI75 (75% improvement of PASI score) and 40% (n=2) 
reaching PASI50 (50% improvement of PASI score), mTOR gene expression was not 
altered by anti-TNF-α treatment (Fig. 5D). 
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Fig. 5. mTOR gene expression in: A) HaCaT cells, B) primary KCs, C) ex vivo full-thickness skin organ 
cultures and D) 5 psoriatic patients before (T0) and after (T1) 16 weeks of treatment with adalimumab; 
A) UVB dose used: 100 mJ/cm²; A-B-C) stimulations with pro-inflammatory stimuli TNF-α (20 ng/ml),  
IL-17A (10 ng/ml), and TNF-α + IL-17A were performed for 24h. Data were compared with untreated 
HaCaT cells, primary KCs, ex vivo skin organ culture and healthy skin, respectively; normalization to the 
housekeeping gene 18S was performed and displayed as mean ± SD of three independent experiments. 
Ctrl=control, KCs=keratinocytes, TNF-α=tumor necrosis factor-α, *p<0.05, **p<0.01, ***p<0.001. 
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mTOR expression is modulated in acne 
Recently, mTOR has emerged having a role in acne pathogenesis, but very little is 
known. For this reason we extend our study analyzing gene profile expression of mTOR, 
its upstream regulators (TSC1 and 2) and its downstream effectors (4EBP1 and S6K1) in 
lesional and non-lesional skin biopsies of patients with acne. mTOR gene expression was 
significantly increased in acne, both in non-lesional and lesional skin respect to healthy 
controls, as well as IL-8 (Fig. 6A). As an additional confirmation, immunohistochemical 
studies demonstrated that mTOR was effectively over-expressed. In particular, mTOR 
kinase was equally strong expressed through all epidermal layers in lesional as well as 
non-lesional acneic skin; but only weakly expressed in the epidermis from healthy 
individuals (data not shown). 
Conversely, mRNA levels of TSC1 and TSC2, 4EBP1 and S6K1 were not enhanced in 
acne.  
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Fig. 6 mTOR, IL-8, TSC1 ,TSC2, 4EBP1 and S6K1 gene expression in acneic non lesional and lesional skin. 
Data were compared with healthy skin, normalized to the housekeeping gene 18S and expressed as mean ± 
SD. 4EBP1= Eukaryotic translation initiation factor 4E-binding protein 1 S6K= Ribosomal protein S6 
kinase beta-1, SD=standard deviation, (S6K), TSC1=tuberous sclerosis protein 1, TSC2=tuberous sclerosis 
protein 2,  *p<0.05, **p<0.01, ***p<0.001 
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Discussion 
Although numerous literature evidences suggest a pro-inflammatory role for mTOR (12-15, 
106-109), little is known about its relationships with skin inflammation. We investigated 
whether mTOR was involved in some of the most common skin inflammatory diseases, 
evaluating its mRNA levels in psoriasis, ACD and AD. Our results showed that mTOR gene 
expression was significantly increased in these dermatoses. Moreover, the evaluation of 
mTOR gene expression in EGFR-inhibitor-induced skin reaction confirmed the modulation 
of mTOR pathways as a constant marker of skin inflammatory processes. However, mTOR, a 
serine/threonine kinase, functions as a central node in a complex network of 
phosphorylation/dephosphorylation signaling pathways that activate the translational 
machinery and promote cell growth. For this reason, the enhancement of mTOR previously 
found do not explain its activation in the investigated skin inflammatory diseases thought a 
traditional post-translational pathway. These results were confirmed and validated by the 
investigation of the expression of the major negative up-stream regulators of mTOR such as 
TSC1 and 2. Indeed, it is well known that TSC1 and 2 negatively regulates the kinase activity 
of mTORC1 by converting a GTP-binding protein, Ras omolog enriched in brain (Rheb), 
into its inactive GDP-bound state (134). TSC1 and TSC2 gene expression was not increased 
in psoriasis and ACD and significantly reduced in AD compared to healthy skin; as regards 
EGFR inhibitor induced cutaneous rash, TSC1 levels were not significantly increased, 
whereas TSC2 gene expression was reduced. Therefore, these gene expression data did not 
provide evidence that Akt activates mTOR, at least in part, through the phosphorylation and 
inactivation of TSC1/2 heterodimer. Further evidences about mTOR over-expression in skin 
inflammatory diseases were powered by immunohistochemical studies on skin biopsies of 
lesional and non lesional psoriatic skin. A strong expression of mTOR was found through all 
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epidermal layers in both lesional and non lesional psoriatic skin compared to the epidermis 
from healthy individuals. Particularly concerning psoriasis, our data are in line with those 
reported by Buerger et al. who recently showed for the first time an increase in mTOR 
expression and phosphorylation at Ser2448 (a site representative for mTOR activation) in 
lesional and non-lesional psoriatic skin compared to healthy skin through 
immunoistochemical and immunofluorescent studies, respectively (135).  On the other hand, 
mTOR mRNA level was decreased in PBMC of psoriatic patients, suggesting that mTOR 
signalling might be specifically involved in skin inflammation rather than in a systemic 
lymphocytes activation. All these data underline the possible involvement of mTOR in 
cutaneous inflammatory diseases. It is reported that mTOR is implicated in the development 
of several inflammatory and metabolic disorders, such as diabetes, metabolic syndrome, 
rheumatoid arthritis and Crohn’s disease (136-141). Chong et al. reported that mTOR can 
alter insulin signalling leading to insulin resistance in the cardiovascular system during 
diabetes mellitus (136), whereas Dazer et al. underlined that alterations of mTOR signalling 
pathway, especially regarding energy homeostasis and metabolism, are implicated in 
metabolic syndrome, which is strictly correlated to diabetes (12). Furthermore, mTOR 
represents an important linkage between synovitis and structural damage in rheumatoid 
arthritis and its inhibition by rapamycin or everolimus is able to reduce synovial osteoclast 
formation, protecting against local bone erosions and cartilage loss (13). In addition, mTOR 
has been reported to be related to the triggering of Crohn’s disease; Indeed, mTOR plays a 
major role in the regulation of autophagy (137) whose impairment represents a critical 
initiating point in this disease pathogenesis (138, 139). Moreover, inhibitors of mTOR are 
reported to be useful in treating Crohn’s disease, as highlighted by several case reports (140, 
141). To gain additional information about the involvement of mTOR in the pathogenesis of 
skin inflammatory diseases we also evaluated the gene expression of its main down-stream 
outputs such as 4EBP1 and S6K1. Nor 4EPB1 neither S6K1 were significantly enhanced in 
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psoriasis, ACD, AD as well as EGFR  inhibitor induced cutaneous rash. Therefore, it seems 
that mTOR pathway activated in skin inflammatory diseases may be different from the 
traditional one implicating 4EBP1 and/or S6K1. However, these data were not sufficient for 
arising such conclusion because mTOR regulates protein synthesis mainly through the 
phosphorylation and inactivation of  4EBP1 and through the phosphorylation and activation 
of S6K1. Indeed, very recently Buerger et al. (135) showed that S6K1 is activated in 
psoriasis lesions compared to non-lesional skin as well as one of its major target, the 
ribosomal protein S6.  Nevertheless, the authors analyzed only a very small group of subjects 
(3 psoriatic patients); furthermore, the activation of S6K1 was found in only 2 out of 3 
psoriatic patients. Therefore, the pathway triggered by mTOR in psoriasis and consequently 
in skin inflammation is still not so clear; more studies and researches are needed to clarify its 
potential involvement in the disease. 
Hence, to further analyze the role of mTOR in skin inflammation, we reproduced a psoriasis-
like pro-inflammatory milieu in vitro, stimulating KCs as well as skin organ culture with 
TNF-α, IL-17A and their combination; No alterations of mTOR gene expression were 
encountered. Young et al. (142) showed that rapamycin reduced TNF-α expression in KCs, 
and so hypothesized that, TNF-α could be able to enhance mTOR, being so implicated in 
cutaneous inflammation. Conversely, Williamson et al. reported that elevated concentrations 
of TNF-α in circulating blood or in cell culture medium of C2C12 myotubes inhibit insulin-
mTOR-stimulated pathways (143).  
Furthermore, Di-Lin et al. showed that mTOR inhibits the anti-inflammatory action of Liver 
X Receptor (LXR-α) and Pregnane X Receptor (PXR) in TNF-α-mediated responses, 
suggesting that it may act as a negative regulator of lipid homeostatsis (145). 
We found that UVB irradiation did enhance mTOR in the 3 analyzed models. The 
mechanisms by which UV modulates inflammation, in the immunoactivation-
immunosuppression balance, is complex and not completely understood, but it is well know 
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its ability in increasing multiple pro-inflammatory cytokines. Our data are in line with 
previous studies which reported that UVB induced mTOR activation in HaCat cells (146) 
and primary KCs (147). On the light of these in vitro results, we decided to assess whether 
mTOR expression was influenced by anti TNF-α therapy. Interestingly adalimumab 
treatment did not reduce mTOR mRNA expression, although all patients reported clinical 
improvement. All together, these results suggested that mTOR is involved in cutaneous 
inflammatory process, but through a signalling not directly dependent from Th1-Th17 
pathway.  
Recently, mTOR has emerged having a role in acne pathogenesis, but very little is known. 
For this reason we extend our study analyzing gene profile expression of mTOR, its upstream 
regulators (TSC1 and 2) and its downstream effectors (4EBP1 and S6K1) in lesional and 
non-lesional skin biopsies of patients with acne. However, the not increased mRNA levels of 
mTOR downstream effectors 4EBP1 and S6K1 found in our experiments do not imply that 
mTORC1 is not activated in the inflammatory mechanism of acne. Indeed, placebo-
controlled studies have demonstrated that high glycaemic load diets aggravate acne, result in 
postprandial hyperinsulinaemia and increase serum levels of free IGF-1 (112-114). 
Epidemiological as well as clinical evidence confirmed that milk and other insulinotropic 
dairy products induce or aggravate acne (114) because milk functions as an endocrine 
growth–promoting signalling system of mammals, which activates mTORC1 signalling but 
inhibits FoxO1-dependent gene regulation (110). FoxO1 is an important transcription factor 
that, like mTORC1, modulates the expression of genes involved in the regulation of cell 
proliferation, apoptosis, anti-oxidative stress responses and regulation of glucose and lipid 
metabolism. In particular, increased insulin/IGF-1 signaling and activation of the PI3K/Akt-
pathway results in Akt-mediated nuclear phosphorylation of FoxO1 protein, thereby 
promoting its extrusion from the nucleus into the cytoplasm where it is inhibited. This 
shuttling mechanism functions as a molecular switch for FoxO1-mediated gene regulation. 
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Moreover, FoxO1 not only suppresses protein synthesis and cell growth, but also lipid 
metabolism because regulates the key transcription factor of lipid synthesis, SREBP (116). 
IGF-1, through mTORC1 activation, induced SREBP expression and enhanced lipogenesis in 
sebocytes via activation of the PI3K/Akt pathway, whereas FoxO1 antagonized the 
expression of SREBP. 
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Conclusions 
In conclusion, our study provides evidence that mTOR is involved in cutaneous 
inflammatory process but deeper insights into the comprehension of its molecular pathway 
may help to understand the effective role of mTOR in the pathogenesis and treatment of 
diseases such as psoriasis and acne. Specially, our findings highlight the necessity of 
investigating activated mTOR protein as well as its upstream regulators and downstream 
effectors to better penetrate the complex biology of mTOR. 
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